Braver Wealth Management’s Teva Pharmaceuticals TEVA Stock Holding History

Braver Wealth Management’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-37,770	Closed	-$1.74M	–	157
2016 Q3	$1.74M	Buy	+37,770	New	+$1.97M	0.29%	78
2015 Q2	–	Sell	-35,518	Closed	-$2.21M	–	95
2015 Q1	$2.21M	Sell	35,518 -1,169	-3%	-$68K	0.45%	41
2014 Q4	$2.11M	Buy	36,687 +8,601	+31%	+$479K	0.43%	41
2014 Q3	$1.51M	Sell	28,086 -187	-0.7%	-$9.91K	0.45%	36
2014 Q2	$1.48M	Sell	28,273 -189	-0.7%	-$9.66K	0.38%	46
2014 Q1	$1.5M	Sell	28,462 -30	-0.1%	-$1.39K	0.43%	39
2013 Q4	$1.14M	Sell	28,492 -8,220	-22%	-$324K	0.39%	49
2013 Q3	$1.39M	Buy	+36,712	New	+$1.43M	0.48%	41

Other funds holding TEVA

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Barrow, Hanley, Mewhinney & Strauss Dallas, Texas $30.5B AUM 29.95% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

HCM

Highfields Capital Management Boston, Massachusetts $68.3M AUM 21.64% 1-Year Est. Return

Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Nordea Investment Management Stockholm, Sweden $107B AUM 24.58% 1-Year Est. Return

Braver Wealth Management's TEVA Position: Q4 2016 in Review

Braver Wealth Management sold out of Teva Pharmaceuticals (TEVA) in Q4 2016, closing a stake of 37,770 shares — an estimated $1.74M sold.

Braver Wealth Management first reported a position in TEVA in Q3 2013 and held it in 8 quarters. The position peaked at $2.21M in Q1 2015. 737 funds tracked by Wall St. Rank hold TEVA as of Q4 2016.

Braver Wealth Management reported no remaining Teva Pharmaceuticals position as of Q4 2016 after selling out during the quarter.
Braver Wealth Management sold 37,770 Teva Pharmaceuticals shares in Q4 2016, an estimated $1.74M.
Braver Wealth Management first reported a position in Teva Pharmaceuticals in Q3 2013 and held it in 8 quarters.
Braver Wealth Management's Teva Pharmaceuticals position peaked at $2.21M in Q1 2015.
737 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q4 2016.

Based on Braver Wealth Management's 13F filing for Q4 2016, filed 14 Feb 2017.